Charts

Oral Presentation to Feature Results from ZETA-1 Phase 2 Trial of APX3330 in Diabetic Retinopathy Patients Results from Phase 3 LYNX-1 Trial of Nyxol® in Dim Light Vision Disturbance to be Presented for the First Time to the Medical Community FARMINGTON HILLS, Mich., March 23, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disor

Topline Data from ZETA-1 Phase 2 Trial of Oral APX3330 in Diabetic Retinopathy Presented on February 11th at 20th Angiogenesis, Exudation, and Degeneration 2023 Meeting Topline Data from ZETA-1 Accepted for Presentation on February 17th at Macula Society 46th Annual Meeting Presentations Highlight Binocular 3-Step or More DRSS Worsening Measure in the ZETA-1 Phase 2 Trial; This Pre-Specified Secondary Endpoint Met by APX3330 is the Planned Potential Phase 3 Primary Registration Endpoint FARMINGT

Gainers Clene (NASDAQ:CLNN) stock increased by 51.9% to $2.05 during Monday's pre-market session. The company's market cap stands at ...

If Approved Later This Year, Nyxol Could be the Only Commercially Available Eye Drop for Reversal of DilationFARMINGTON HILLS, Mich., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for Nyxol® (phentola

Gainers Vaccitech (NASDAQ:VACC) shares rose 8.5% to $3.2 during Friday's after-market session. The company's market cap stands at ...

Gainers MicroAlgo Inc. (NASDAQ: MLGO) shares jumped 74% to $2.90. MicroAlgo recently entered into securities purchase agreement ...

Gainers Akanda (NASDAQ:AKAN) shares moved upwards by 157.0% to $0.49 during Thursday's regular session. Trading volume for Akanda's ...

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining over 100 points on Thursday. Following the market opening ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Inhibikase Therapeutics (IKT) stock is falling on Thursday after the company announced a registered direct offering and private placement. The post Why Is Inhibikase Therapeutics (IKT) Stock Down 11% Today? appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today It doesn’t matter if you have $500 or $5 million. Do this now. Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Ocuphire Pharma (OCUP) stock is falling on Thursday after the company posted mixed results from a Phase 2 clinical trial. The post Why Is Ocuphire Pharma (OCUP) Stock Down 20% Today? appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today It doesn’t matter if you have $500 or $5 million. Do this now. Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

Gainers Minerva Surgical (NASDAQ:UTRS) stock moved upwards by 82.4% to $0.69 during Thursday's pre-market session. The company's market ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips We're starting off the day with an overview of the biggest pre-market stock movers that traders need to watch on Thursday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today It doesn’t matter if you have $500 or $5 million. Do this now. Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

Gainers GT Biopharma (NASDAQ:GTBP) shares increased by 7.4% to $0.91 during Wednesday's after-market session. The market value of their ...

Oral APX3330 Achieved Statistical Significance on a Key Pre-specified Secondary Endpoint of Preventing Clinically Meaningful Progression of Diabetic Retinopathy (DR) after 24 Weeks of Treatment Oral APX3330 Demonstrated Favorable Safety and Tolerability Allowing for a Potential Attractive Non-Invasive Option for Protection of Vision in Both Eyes in DR Patients Conference Call and Webcast Today at 4:30pm ET FARMINGTON HILLS, Mich., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq:

Nyxol® Eye Drops Potentially Offer Differentiated Mechanism of Action to Treat Age-Related Blurry Near Vision Launch of Presbyopia Phase 3 Program Supported by Positive Clinical Results that Demonstrated Durable Efficacy and Favorable Safety Profile FARMINGTON HILLS, Mich., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye

NDA Supported by Positive Phase 3 Data Demonstrating Rapid Reversal of Dilated Eyes and Favorable Safety Profile in Pediatric and Adult SubjectsFARMINGTON HILLS, Mich., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Admin

The Planet MicroCap Showcase: VIRTUAL taking place on December 6-8, 2022, where 49 MicroCap public companies will be presenting virtually.

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Micro-Cap ETF (IWC), we found that the implied analyst target price for the ETF based upon its underlying holdings is $163.08 per unit.

FARMINGTON HILLS, Mich., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced that Mina Sooch, MBA, founder and CEO will present at several investor conferences in November and December, including the BTIG Ophthalmology Day, Alliance Global Partners (AGP) Biotech Conference, Ophthalmology Innovation

Gainers Unique Fabricating, Inc. (NYSE: UFAB) jumped 56.3% to close at $0.8205 on Tuesday. Unique Fabricating posted a Q3 loss of ...

Gainers NeoGenomics (NASDAQ:NEO) stock increased by 29.1% to $9.17 during Tuesday's regular session. Trading volume for this ...

Gainers IceCure Medical Ltd (NASDAQ: ICCM) shares jumped 39.4% to $1.4529 after the company announced a payment assignment from ...

Ocuphire Pharma Inc(NASDAQ: OCUP) concluded anexclusive license agreementwithFamyGen Life Sciences ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips We're starting off the day with a look at the biggest pre-market stock movers traders need to know about on Tuesday morning! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.

Gainers NeuroBo Pharmaceuticals (NASDAQ:NRBO) shares rose 49.1% to $3.22 during Tuesday's pre-market session. The ...

Gainers Ocuphire Pharma, Inc. (NASDAQ: OCUP) shares rose 27.8% to $2.67 in pre-market trading. Ocuphire Pharma entered into a ...

Ocuphire to Receive $35 Million Upfront, Nyxol Development Funding and Additional Potential Milestone Payments plus Tiered Double-Digit Royalties Strengthened Financial Position Supports Operations and APX3330 Program into 2025 Conference Call Tomorrow November 8, 2022 at 8:30 AM ET FARMINGTON HILLS, Mich., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) today announced it has concluded an exclusive license agreement with FamyGen Life Sciences, Inc. (Famy) for the developm

NDA Submission for Nyxol for RM and Initiation of VEGA-2 on Track for Q4 2022 Topline Data from ZETA-1 Phase 2b Trial of Oral APX3330 Expected in Early 2023 FARMINGTON HILLS, Mich., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, announces financial results for the third quarter ended September 30, 2022 and pr

FARMINGTON HILLS, Mich., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced that the positive results in night vision disturbances (NVD) patients from its earlier and first Phase 2 study evaluating the safety and efficacy of phentolamine mesylate eye drops (Nyxol) have been peer-reviewed and publi

Gainers Ensysce Biosciences (NASDAQ:ENSC) stock increased by 47.9% to $0.31 during Wednesday's pre-market session. The ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips It's time to start off the day with a breakdown of the biggest pre-market stock movers for Wednesday morning and the latest news! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.

FARMINGTON HILLS, Mich., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced acceptance and presentation of six posters featuring Nyxol® and APX3330 at the American Academy of Optometry (AAOPT) 2022 Annual Meeting being held October 26-29, 2022 in San Diego, CA. AAOPT 2022: San Diego Convention Cen

Ocuphire to Present on Wednesday, October 12th @ 2:30 PM CTFARMINGTON HILLS, Mich., Oct. 07, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced that CEO and Founder Mina Sooch will present a corporate overview at at the MicroCap Rodeo Windy City Roundup 2022 Conference. The conference is being held on Octo

Virtual Webinar to Take Place Friday, October 14th @ 11 AM ET Topline Results from ZETA-1 Phase 2b Trial of APX3330 Expected Later in 4Q 2022 FARMINGTON HILLS, Mich., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced that it will host a key opinion leader (KOL) webinar highlighting oral APX3330,

FARMINGTON HILLS, Mich., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced that it has appointed seven new Key Opinion Leaders (KOLs) across retina, cornea/refractive, and medical optometry to its Medical Advisory Board (MAB). In addition, Ronil Patel, M.S. has been promoted to Vice President, B

FARMINGTON HILLS, Mich., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced that Mina Sooch, CEO and Founder will present a company overview at the Ophthalmology Futures Forums European Forum 2022 on September 15, 2022. At the [email protected] 2022 on September 29, 2022, Mina Sooch will present a

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Micro-Cap ETF (IWC), we found that the implied analyst target price for the ETF based upon its underlying holdings is $178.81 per unit.

NDA Submission for Nyxol Eye Drops in First Indication on Track for Late 2022FARMINGTON HILLS, Mich., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted a small business waiver of the Prescription Drug User Fee Act (PDUFA) fee of $3.1 m

The United States Food and Drug Administration (FDA) has approved Revance Therapeutics’ (NASDAQ: RVNC) lead asset DAXXIFY ...

Top-line Results are Expected in 4Q 2022 Interim Masked Safety Results Seen Demonstrate Favorable Safety and Tolerability Profile, Consistent with 11 Prior Trials of APX3330 Oral APX3330 has the Potential to Serve a Market of More Than 8 Million Diabetic Retinopathy Patients with Limited Treatment Options FARMINGTON HILLS, Mich., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing

FARMINGTON HILLS, Mich., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced that Mina Sooch, MBA, Founder and CEO will present a corporate overview at the H.C. Wainwright 24th Annual Global Investment Conference being held September 12-14, 2022. H.C. Wainwright 24th Annual Global Investment Confe

Completed Final Clinical Trials and Pre-NDA FDA Meeting to Support Registration of Nyxol in Reversal of Mydriasis (RM), On Track for Late 2022 NDA Submission and Potential 2023 Approval Positive Results from Phase 3 LYNX-1 Trial of Nyxol in Night Vision Disturbances (NVD) Mark Sixth Positive Nyxol Clinical Data Readout Across Multiple Indications Data Expected in 2H 2022 from Phase 2b Trial of APX3330, a Potential First-in-Class Oral Treatment for Diabetic Retinopathy Plans to Initiate VEGA Phas

Gainers Digital Media Solutions, Inc. (NYSE: DMS) jumped 78.8% to close at $2.11. Digital Media Solutions recently reported ...

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CDC Recommends COVID-19 ...

Gainers Exicure (NASDAQ:XCUR) shares rose 24.8% to $0.15 during Friday's pre-market session. The company's ...

Ocuphire Pharma Inc(NASDAQ: OCUP) hasannounced topline resultsfrom the LYNX-1 Phase 3 trial investigating Nyxol for ...

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Enanta's RSV Candidate ...

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Core S&P Total US.

Biotech stocks posted weekly declines yet again in the week endingApril 29, takingcues from the weak broader market ...

Biotech stocks extended their loses in the week endingApril 22. The sector took cues from the broader market, which reacted to the ...

Gainers IGM Biosciences, Inc. (NASDAQ: IGMS) shares gained 96.7% to settle at $29.49 on Tuesday. Sanofi SA (NASDAQ: SNY) and IGM ...

Gainers China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) jumped 88.1% to $0.38 after declining 9% on Monday. McCormick (NASDAQ: ...

Ocuphire Pharma Inc(NASDAQ: OCUP)announced topline resultsfrom the second Phase 3 MIRA-3 trial of Nyxol to reverse ...

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Announces Publication ...

Gainers Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) rose 41.6% to $3.13 in pre-market trading after gaining around ...

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Micro-Cap ETF (IWC), we found that the implied analyst target price for the ETF based upon its underlying holdings is $202.26 per unit.

Gainers ACADIA Pharmaceuticals (NASDAQ:ACAD) stock rose 24.26% to $24.11 during Monday's after-market session. Today's trading volume ...

Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) shares gained 689.4% to settle at $78.94 on Wednesday after the company priced ...

Toward the end of trading Wednesday, the Dow traded down 0.21% to 35,738.42while the NASDAQ rose 0.06% to 15,784.86. The S&P ...

Gainers Biofrontera (NASDAQ:BFRI) shares increased by 160.83% to $6.86 during Wednesday's regular session. The company's market cap ...

Midway through trading Wednesday, the Dow traded down 0.28% to 35,714.19 while the NASDAQ fell 0.29% to 15,729.96. The S&P also ...

Gainers Biofrontera Inc. (NASDAQ: BFRI) shares jumped 109.5% to $5.51 after Roth Capital initiated coverage on the stock with a ...

Upgrades For Aegon NV (NYSE:AEG), Credit Suisse upgraded the previous rating of Neutral to Outperform. At the moment, ...